Antithrombotic Therapy in Patients with Coronary Artery Disease and Prior Stroke

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Patients with coronary artery disease (CAD) and prior cerebrovascular events (CVE) face high risks of ischemic and bleeding events.
• Antithrombotic management in this high-risk group presents significant clinical challenges.
• Potent antiplatelet therapy may be safe acutely but increases major bleeding risk with prolonged use.

Purpose of the Study:

• To critically evaluate evidence on antithrombotic therapy for patients with CAD and prior CVE.
• To guide clinical decisions in balancing ischemic and bleeding risks in this population.
• To identify optimal antithrombotic strategies for high-risk patients.

Main Methods:

• Systematic review of recent clinical trials and available evidence.
• Critical appraisal of antithrombotic strategies in managing patients with comorbid CAD and CVE.
• Analysis of risk-benefit profiles of different antithrombotic regimens.

Main Results:

• Potent antiplatelet strategies are effective in acute myocardial ischemia phases.
• Prolonged antithrombotic therapy significantly elevates the risk of major bleeding, including intracranial hemorrhage.
• Careful balancing of ischemic versus bleeding risks is essential for chronic management.

Conclusions:

• Antithrombotic management for patients with CAD and prior CVE requires a personalized approach.
• The duration and intensity of antithrombotic therapy must be carefully weighed against bleeding risks.
• Further research is needed to optimize antithrombotic strategies for this complex patient subgroup.